Zhejiang Langhua Pharmaceutical Co., Ltd. Company Profile

Background

Zhejiang Langhua Pharmaceutical Co., Ltd., established in 1986, is a comprehensive pharmaceutical company specializing in the research, development, production, marketing, and sourcing of pharmaceutical products. As a subsidiary of Viva Biotech Holdings, a leader in innovative drug discovery, Langhua offers a one-stop Contract Development and Manufacturing Organization (CDMO) solution for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF), covering the entire drug lifecycle from pre-clinical stages to commercial supply.

The company's mission is to contribute to healthcare by enhancing the availability and affordability of medicines. Its vision is to become the most valuable and preferred innovative API manufacturer and CDMO partner.

Key Strategic Focus

Langhua Pharmaceutical's strategic focus encompasses:

Comprehensive CDMO Services: Providing end-to-end solutions for small molecule APIs and FDFs, from pre-clinical development to commercial manufacturing.

Global Quality Compliance: Maintaining robust quality management systems that meet international standards, including certifications from the U.S. FDA, EDQM, WHO, ANVISA, PMDA, and NMPA.

Innovative R&D Network: Operating three strategic R&D centers in Shanghai, Ningbo, and Taizhou, with over 13,000 square meters of laboratory space and a team of more than 700 researchers.

Diverse Product Portfolio: Manufacturing a range of products, including Spironolactone, Olanzapine, antiviral agents, and fluoroquinolones, serving global customers with high-quality and competitive generic APIs.

Financials and Funding

In August 2020, Viva Biotech acquired an 80% equity interest in Langhua Pharmaceutical for RMB 2.56 billion. This strategic acquisition aimed to integrate and enhance the service chain of the innovative drug industry, enabling Langhua to expand its CDMO capabilities and customer base.

Pipeline Development

Langhua Pharmaceutical has contributed to the launch of over 20 new drugs in recent years, with a product line spanning oncology, HIV, diabetes, and cardiovascular fields. The company offers comprehensive CDMO services, supporting clients from pre-clinical development through to commercial manufacturing.

Technological Platform and Innovation

Langhua's technological platforms and innovations include:

Advanced R&D Facilities: Equipped with state-of-the-art laboratory equipment and analytical instruments, such as NMR, LC-MS, TOF-MS, SFC, GC-MS/MS, ICP-MS, LC-CAD, XRPD, IR, and UPLC, facilitating effective API and formulation development.

Comprehensive Quality Management: Implementing robust quality management systems, Environment, Health, and Safety (EHS) protocols, and intellectual property protection mechanisms to ensure compliance with international standards.

Leadership Team

Langhua Pharmaceutical's leadership team comprises experienced professionals with extensive backgrounds in the pharmaceutical industry:

Dr. Cheney Mao: Chairman and CEO of Viva Biotech, overseeing strategic planning and business development.

Dr. Zhixiong Ye: Chief Scientific Officer of Viva Biotech, with over 13 years of experience at Merck & Co., focusing on drug research and development for diabetes, obesity, and endocrine-related diseases.

Mr. Wei Xiong: Chief Financial Officer, responsible for financial management, with a background in international economics and trade, and law.

Dr. Yonghui Ge: Vice President of Viva Biotech, holding a Ph.D. in Pharmaceutics from Hokkaido University, Japan, with nearly 20 years of experience in small molecule innovative drug development and project management.

Mr. Weidong Zhang: Senior Vice President of Viva Biotech, Executive Vice President and Manufactory General Manager of Langhua Pharmaceutical, with nearly 30 years of experience in the pharmaceutical API industry and over 10 years of international CDMO collaboration experience.

Dr. Jianguo Ma: Senior Vice President of Viva Biotech, with a Ph.D. from the University of Montreal and postdoctoral experience at Harvard University, specializing in CMC experiences for APIs of innovative and generic drugs.

Dr. Cunxiang Zhao: Vice President of Viva Biotech, responsible for the CDMO business, with extensive experience in medicinal chemistry, process development, and GMP production.

Leadership Changes

In August 2020, Viva Biotech acquired an 80% equity interest in Langhua Pharmaceutical, leading to strategic integration and expansion of the service chain in the innovative drug industry.

Competitor Profile

Market Insights and Dynamics

China's pharmaceutical industry is one of the largest globally, with a market size of approximately US$110 billion as of 2017. The industry is characterized by rapid growth, a vast consumer base, and increasing investments in research and development.

Competitor Analysis

Key competitors in the Chinese pharmaceutical industry include:

WuXi AppTec: A leading global pharmaceutical, biotechnology, and medical device open-access capability and technology platform company, offering comprehensive services in drug discovery, development, and manufacturing.

Asymchem Laboratories: A CDMO providing integrated solutions for pharmaceutical companies, specializing in process development and manufacturing of APIs and intermediates.

Porton Pharma Solutions: A CDMO offering services in process development, scale-up, and commercial production of APIs and intermediates.

These competitors focus on providing comprehensive CDMO services, leveraging advanced technologies and extensive experience in the pharmaceutical industry.

Strategic Collaborations and Partnerships

Langhua Pharmaceutical has established significant collaborations to strengthen its market position and innovation capacity:

VivaVision: Supported the scale-up production of clinical samples for VivaVision's VVN001, a second-generation LFA-1 antagonist undergoing Phase II clinical studies for dry eye treatment in the United States.

Operational Insights

Langhua's strategic considerations include:

Quality Compliance: Maintaining certifications from international regulatory authorities, ensuring adherence to global quality standards.

EHS Compliance: Implementing robust Environment, Health, and Safety systems, setting benchmarks in the API industry in China.

Production Capacity: Operating 12 cGMP manufacturing workshops with reactor volumes ranging from 50L to 12,000L, capable of handling various reactions and ensuring on-time delivery from kilograms to tons.